Evidence map›Paper›PMID 26883642›Full record

ArticleNeurochemical research2016

Proof-of Concept that an Acute Trophic Factors Intervention After Spinal Cord Injury Provides an Adequate Niche for Neuroprotection, Recruitment of Nestin-Expressing Progenitors and Regeneration.

Warin Krityakiarana, Paul M Zhao, Kevin Nguyen, Fernando Gomez-Pinilla, Naiphinich Kotchabhakdi, Jean de Vellis, Araceli Espinosa-Jeffrey

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurochemical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Executive Dysfunction Early Postnatal Biomarkers among Children Born Extremely Preterm.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Warin KrityakiaranaDepartments of Neurobiology, Psychiatry and Biobehavioral Sciences, Intellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at University of California, Los Angeles, 635 Charles E. Young Drive South, Suite 375E, Los Angeles, CA, 90095-7332, USA. warink@swu.ac.th.
Paul M ZhaoDepartments of Neurobiology, Psychiatry and Biobehavioral Sciences, Intellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at University of California, Los Angeles, 635 Charles E. Young Drive South, Suite 375E, Los Angeles, CA, 90095-7332, USA.
Kevin NguyenDepartments of Neurobiology, Psychiatry and Biobehavioral Sciences, Intellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at University of California, Los Angeles, 635 Charles E. Young Drive South, Suite 375E, Los Angeles, CA, 90095-7332, USA.
Fernando Gomez-PinillaDepartment of Physiological Sciences and Department of Neurosurgery, University of California at Los Angeles, Los Angeles, CA, USA.
Naiphinich KotchabhakdiNeuro-Behavioural Biology Center, Institute of Science and Technology for Research and Development, Mahidol University, 999 Phutthamonthol 4 Road, Salaya, Phutthamonthol, Nakornpathom, 73170, Thailand.
Jean de VellisDepartments of Neurobiology, Psychiatry and Biobehavioral Sciences, Intellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at University of California, Los Angeles, 635 Charles E. Young Drive South, Suite 375E, Los Angeles, CA, 90095-7332, USA.
Araceli Espinosa-JeffreyDepartments of Neurobiology, Psychiatry and Biobehavioral Sciences, Intellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at University of California, Los Angeles, 635 Charles E. Young Drive South, Suite 375E, Los Angeles, CA, 90095-7332, USA. aespinosa@mednet.ucla.edu.
University of California, Los Angeles · USMahidol University · THThe University of Tokyo · JP

Funding

Stem CellsP30HD004612 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOOKHEIMER, SUSAN Y · 1985 to 2014
$19.5M
VIP AND PACP ACTION IN CNS DEVELOPMENT AND INJURYP01HD006576 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DE VELLIS, JEAN · 1985 to 2006
$7.8M
UCLA Center for Translational Research in Neurodevelopment: UC-TRaNU54HD087101 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCCRACKEN, JAMES T. · 2016 to 2020
$6.5M
Restoration of Homeostasis After Brain TraumaR01NS050465 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GOMEZ-PINILLA, FERNANDO · 2005 to 2019
$5.5M
NICHD NIH HHS P01 HD006576NICHD NIH HHS P30 HD004612NICHD NIH HHS U54 HD087101NINDS NIH HHS R01 NS050465
6 · The paper itself

Abstract

Trophic factor treatment has been shown to improve the recovery of brain and spinal cord injury (SCI). In this study, we examined the effects of TSC1 (a combination of insulin-like growth factor 1 and transferrin) 4 and 8 h after SCI at the thoracic segment level (T12) in nestin-GFP transgenic mice. TSC1 treatment for 4 and 8 h increased the number of nestin-expressing cells around the lesion site and prevented Wallerian degeneration. Treatment with TSC1 for 4 h significantly increased heat shock protein (HSP)-32 and HSP-70 expression 1 and 2 mm from lesion site (both, caudal and rostral). Conversely, the number of HSP-32 positive cells decreased after an 8-h TSC1 treatment, although it was still higher than in both, non-treated SCI and intact spinal cord animals. Furthermore, TSC1 increased NG2 expressing cell numbers and preserved most axons intact, facilitating remyelination and repair. These results support our hypothesis that TSC1 is an effective treatment for cell and tissue neuroprotection after SCI. An early intervention is crucial to prevent secondary damage of the injured SC and, in particular, to prevent Wallerian degeneration.

Indexed as

AnimalsMiceMice, TransgenicNestinNeuroprotective AgentsSpinal Cord InjuriesStem CellsNestinNeuroprotective AgentsHeat shock proteinsIGF-1MyelinOligodendrocytesTransferrinWallerian degeneration

Identifiers

PMID26883642
PMCPMC5352162
OpenAlexW2282664676

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.